Biopharmaceutical company developing treatments for inflammatory diseases and cancer.
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Celldex Therapeutics, Inc..
The 1 sources with the most insights about Celldex Therapeutics, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
A speaker praised the company and its data, including a drug for hives, but the stock's 20–30% rally and subsequent fade highlighted volatility; no detailed trial or commercial analysis was provided.
A speaker praised the company and its data, including a drug for hives, but the stock's 20–30% rally and subsequent fade highlighted volatility; no detailed trial or commercial analysis was provided.
Other assets that creators frequently mention in the same content as Celldex Therapeutics, Inc..
The most active sources covering Celldex Therapeutics, Inc. (CLDX) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 1 AI-extracted insight about Celldex Therapeutics, Inc. (CLDX) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Celldex Therapeutics, Inc. (CLDX) most frequently also discuss BZ, AMD, LRCX, META, DOGE. See the "Discussed alongside" section above for full asset pages.